Table 1. Clinical characteristics of study groups.
Characteristics | HIV-infected patients (n = 76) | Healthy controls (n = 16) |
Age [median (IQR)] | 32 (28–39.5) | 32 (27–47) |
Male [n (%)] | 58 (76.3%) | 10% (62.5%) |
CD4+ T cell count at baseline (cells/mm3) median (IQR) | 248 (121–297). | N/A |
CD8+ T cell count at baseline (cells/mm3) median (IQR) | 620 (443–917) | N/A |
CD4 to CD8 ratio, median (IQR) | 0.32 (0.18–0.46) | N/A |
HAART regimens | ||
2 NRTIs+1 NNRTIs [n (%)] | 73 (96.1%) | NA |
2 NRTIs+1 PIs [n (%)] | 3 (3.9%) | NA |
Undetectable viral load after 12 months of HAART [n (%)] | 72 (94.7%) | NA |
IQR, interquartile range; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; N/A, not available; NA, not applicable.